Anthem Biosciences Limited (NSE:ANTHEM)

Market Cap	389.31B
Revenue (ttm)	20.02B +12.7%
Net Income	4.85B +2.3%
EPS	8.58 +1.8%
Shares Out	561.61M
PE Ratio	80.83
Forward PE	58.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,498
Average Volume	279,539
Open	693.20
Previous Close	693.20
Day's Range	689.10 - 695.25
52-Week Range	579.15 - 873.50
Beta	n/a
RSI	66.56
Earnings Date	Feb 5, 2026

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,825
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ANTHEM

Financial Performance

In fiscal year 2025, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.